CA2228221C - Papillomavirus polyprotein constructs - Google Patents

Papillomavirus polyprotein constructs Download PDF

Info

Publication number
CA2228221C
CA2228221C CA2228221A CA2228221A CA2228221C CA 2228221 C CA2228221 C CA 2228221C CA 2228221 A CA2228221 A CA 2228221A CA 2228221 A CA2228221 A CA 2228221A CA 2228221 C CA2228221 C CA 2228221C
Authority
CA
Canada
Prior art keywords
leu
thr
val
lys
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2228221A
Other languages
English (en)
French (fr)
Other versions
CA2228221A1 (en
Inventor
Elizabeth Ann Webb
Mary Brigid Margetts
John Cooper Cox
Ian Frazer
Nigel Alan John Mcmillan
Mark Philip Williams
Margaret Bridget Holland Moloney
Stirling John Edwards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
CSL Ltd
Original Assignee
University of Queensland UQ
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ, CSL Ltd filed Critical University of Queensland UQ
Publication of CA2228221A1 publication Critical patent/CA2228221A1/en
Application granted granted Critical
Publication of CA2228221C publication Critical patent/CA2228221C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2228221A 1995-07-27 1996-07-26 Papillomavirus polyprotein constructs Expired - Fee Related CA2228221C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU4439/95 1995-07-27
AUPN4439A AUPN443995A0 (en) 1995-07-27 1995-07-27 Papillomavirus polyprotein
PCT/AU1996/000473 WO1997005164A1 (en) 1995-07-27 1996-07-26 Papillomavirus polyprotein constructs

Publications (2)

Publication Number Publication Date
CA2228221A1 CA2228221A1 (en) 1997-02-13
CA2228221C true CA2228221C (en) 2011-05-17

Family

ID=3788774

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2228221A Expired - Fee Related CA2228221C (en) 1995-07-27 1996-07-26 Papillomavirus polyprotein constructs

Country Status (8)

Country Link
US (2) US6365160B1 (enExample)
EP (2) EP0840747A4 (enExample)
JP (2) JPH11510688A (enExample)
AU (1) AUPN443995A0 (enExample)
CA (1) CA2228221C (enExample)
NZ (1) NZ313108A (enExample)
WO (1) WO1997005164A1 (enExample)
ZA (1) ZA966381B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides
US6030771A (en) * 1997-08-25 2000-02-29 Centers For Disease Control And Prevention Mosaic protein and restriction endonuclease assisted ligation method for making the same
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DK1108035T3 (da) * 1998-09-04 2007-09-24 Sanofi Pasteur Ltd Behandling af cervixcancer
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
ATE418997T1 (de) * 2000-07-06 2009-01-15 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
CN1345775A (zh) 2000-09-30 2002-04-24 养生堂有限公司 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
WO2003068940A2 (en) * 2002-02-14 2003-08-21 Curagen Corporation Complexes and methods of using same
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2002950183A0 (en) * 2002-07-12 2002-09-12 The Council Of The Queensland Institute Of Medical Research Expression of hydrophobic proteins
US7223408B2 (en) 2002-10-03 2007-05-29 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
WO2004105681A2 (en) * 2003-04-28 2004-12-09 Innogenetics N.V. Cd4+ human papillomavirus (hpv) epitopes
US20070160622A1 (en) * 2005-12-07 2007-07-12 Medivas, Llc Method for assembling a polymer-biologic delivery composition
US20080160089A1 (en) * 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
WO2005089164A2 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
JP5178520B2 (ja) * 2005-09-22 2013-04-10 メディバス エルエルシー 固体ポリマー送達組成物およびその使用法
JP5192384B2 (ja) 2005-09-22 2013-05-08 メディバス エルエルシー ビス−(α−アミノ)−ジオール−ジエステル含有ポリ(エステルアミド)およびポリ(エステルウレタン)組成物および使用の方法
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2019645A4 (en) * 2006-05-02 2013-03-06 Medivas Llc RELEASE OF OPHTHALMOLOGICAL ACTIVITIES OUTSIDE OR WITHIN THE EYE
US8101342B2 (en) * 2006-08-28 2012-01-24 Sungkyunkwan University Foundation For Corporate Collaboration DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20090029937A1 (en) * 2007-07-24 2009-01-29 Cornell University Biodegradable cationic polymer gene transfer compositions and methods of use
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN102186484A (zh) * 2008-08-13 2011-09-14 梅迪沃什有限公司 Aabb-聚(酯肽)可生物降解聚合物及其使用方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8642261B2 (en) * 2008-10-31 2014-02-04 Trovagene, Inc. Genetic marker for detection of human papillomavirus
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US9050287B2 (en) * 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
EP2723801B1 (en) 2011-06-23 2017-01-18 DSM IP Assets B.V. New biodegradable polyesteramide copolymers for drug delivery
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
KR20140076613A (ko) * 2011-10-12 2014-06-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법
AU2014248535B2 (en) 2013-03-12 2017-03-30 Inovio Pharmaceuticals, Inc. Improved vaccines for human papilloma virus and methods for using the same
CN107106509B (zh) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 用于递送酸敏感药物的药物递送系统
US12404306B2 (en) 2018-03-06 2025-09-02 Precigen, Inc. Human papillomavirus vaccines and uses of the same
CA3160955A1 (en) 2019-11-12 2021-05-20 Dsm Ip Assets B.V. Polyesteramide copolymers possessing high glass transition temperatures
AU2021385551A1 (en) * 2020-11-25 2023-06-22 Precigen, Inc. Human papilloma virus vaccines and uses of the same for hpv associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
PT97073A (pt) * 1990-03-20 1991-10-31 Behringwerke Ag Processo para a preparacao de epitopos soro-reactivos de proteinas de papillomavirus 16 humano (hpv)
DE4015044A1 (de) * 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
WO1992005248A1 (en) * 1990-09-26 1992-04-02 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
KR100252371B1 (ko) * 1990-12-12 2000-05-01 포터 더글라스 서브유니트 파필로마비루스 백신 및 그들에 사용하기 위한 펩티드
US5464936A (en) * 1990-12-21 1995-11-07 Cetus Oncology Corporation Compositions for identification of papillomavirus replication inhibitors
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
GB9207701D0 (en) * 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
NZ290089A (en) * 1994-07-27 1999-05-28 Queensland Inst Med Res Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
DE4435907C2 (de) 1994-10-07 1997-07-24 Lutz Prof Dr Gissmann Papillomavirusähnliche Partikel und deren Anwendung
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation

Also Published As

Publication number Publication date
US6726912B1 (en) 2004-04-27
EP1847549A3 (en) 2008-01-16
JPH11510688A (ja) 1999-09-21
EP0840747A1 (en) 1998-05-13
NZ313108A (en) 1999-05-28
ZA966381B (en) 1997-05-02
EP0840747A4 (en) 2002-10-23
EP1847549A2 (en) 2007-10-24
CA2228221A1 (en) 1997-02-13
WO1997005164A1 (en) 1997-02-13
AUPN443995A0 (en) 1995-08-17
US6365160B1 (en) 2002-04-02
JP2007054074A (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
US6726912B1 (en) Papillomavirus polyprotein constructs
US6306397B1 (en) Variants of human papilloma virus antigens
JP3958360B2 (ja) 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US5618536A (en) Chimeric papillomavirus-like particles
US7390487B2 (en) Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
HU225893B1 (en) Papilloma virus capsomere vaccine formulations and methods of use
EP1305039B1 (en) Stable (fixed) forms of viral l1 capsid proteins, fusion proteins and uses thereof
US7691386B2 (en) Chimeric papillomavirus-like particles
US6322795B1 (en) Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses
AU699547B2 (en) Papillomavirus polyprotein constructs
KR20050050115A (ko) 유두종바이러스의 2종 이상의 비구조적 초기 단백질을암호화하는 dna 백신
HK1109907A (en) Papillomavirus polyprotein constructs
AU717932B2 (en) Chimeric papillomavirus-like particles
AU717647B2 (en) Chimeric papillomavirus-like particles
WO1998004706A1 (en) Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
KR20000029687A (ko) 면역치료제로서유용한폴리펩티드및폴리펩티드의제조방법
HK1122594A (en) Chimeric human papillomavirus (hpv) l1 molecules and uses therefor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150727